A promising result for the Group’s debut participation, illustrative of an ambitious climate strategy.
Villepinte, France, January 29, 2020 (6:00 pm CET) - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, has received a “B” rating for its first participation in the CDP Climate Questionnaire. CDP is a non-profit organization headquartered in England that singles out the world’s most active companies in the fight against climate change.
The CDP Score Report allows companies to benchmark and compare their progress and environmental impact against peers, to improve their climate change governance and environmental stewardship.
The international organization CDP, formerly known as the Carbon Disclosure Project, encourages investors, companies and cities to take action to build a truly sustainable economy, while helping them to measure and understand their impact on the environment.
In 2019, CDP acted on behalf of over 525 investors with $96 trillion in assets. More than 8,400 companies disclosed environmental data through CDP, representing over 50% of global market capitalization. This provides investors with the crucial environmental data they need to measure the sustainability of their investments by analyzing risks, opportunities and corporate environmental strategies.
Guerbet’s CSR approach is built around 4 pillars, with key objectives and actions planned between now and 2023. One main thrust concerns its EHS policy (environment, health, safety), which gives absolute priority to safety of people while minimizing environmental impacts at all levels.
As part of its EHS policy, Guerbet is committed to implementing solutions to improve its industrial processes and effectively reduce their environmental impact:
- Production process control
- Sustainable use of natural resources
- Measures against climate change
- Process innovation strategy
- Waste control
It is taking action to limit its impact on global warming and help meet the Paris Agreement objective (COP 21 of December 2015), which sets the limit for global temperature rise at less than 2°C by 2100.
The Group is also taking steps to reduce its main sources of emissions:
- A continuous improvement process involving suppliers leaving the largest carbon footprint
- Priority to sea transport over air transport for shipping finished products to customers
- Reduced energy consumption at all industrial sites.
 CDP: Carbon Disclosure Project. Disclosure Insight Action.
Guerbet is a pioneer in the contrast-agent field, with more than 90 years’ experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed amongst its centers in France, Israel and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €790 million in revenue in 2018. For more information about Guerbet, please visit www.guerbet.com.